Janssen-Cilag International NV

🇧🇪Belgium
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-02-19
Last Posted Date
2019-01-23
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
13
Registration Number
NCT03437590
Locations
🇧🇪

UZ Leuven Gasthuisberg, Leuven, Belgium

A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants

First Posted Date
2017-08-15
Last Posted Date
2017-12-11
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
24
Registration Number
NCT03249402
Locations
🇧🇪

SGS Life Science Services, Antwerpen, Belgium

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis

Active, not recruiting
Conditions
Interventions
First Posted Date
2017-07-14
Last Posted Date
2024-12-06
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
133
Registration Number
NCT03218488
Locations
🇩🇪

Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, Germany

🇦🇹

Uniklinik Graz, Graz, Austria

🇧🇪

UCL Hopital Saint-Luc, Bruxelles, Belgium

and more 27 locations

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants

First Posted Date
2017-05-12
Last Posted Date
2018-04-19
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
98
Registration Number
NCT03151486
Locations
🇧🇪

Clinical Pharmacology Unit, Merksem, Belgium

A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults

Phase 1
Completed
Conditions
Interventions
First Posted Date
2017-04-10
Last Posted Date
2018-08-13
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
18
Registration Number
NCT03105986
Locations
🇩🇪

Charité Research Organisation GmbH, Berlin, Germany

A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739

Phase 1
Completed
Conditions
Interventions
First Posted Date
2017-03-23
Last Posted Date
2018-10-26
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
16
Registration Number
NCT03088644
Locations
🇧🇪

UZ Leuven, Leuven, Belgium

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2017-01-18
Last Posted Date
2017-05-25
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
45
Registration Number
NCT03023852
Locations
🇧🇪

SGS Life Science Services, Antwerp, Belgium

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-08-02
Last Posted Date
2018-06-19
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
90
Registration Number
NCT02852395
Locations
🇬🇧

University of Surrey, Guildford, United Kingdom

🇬🇧

Quotient Clinical Limited, United Kingdom, United Kingdom

Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-06-24
Last Posted Date
2020-01-09
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
80
Registration Number
NCT02812251
© Copyright 2024. All Rights Reserved by MedPath